InvestorsHub Logo
Followers 8
Posts 1427
Boards Moderated 0
Alias Born 06/30/2016

Re: numbersarefun post# 38562

Monday, 04/15/2019 7:46:09 AM

Monday, April 15, 2019 7:46:09 AM

Post# of 38634
Numbers, nice to see you here. well sorta that means your holding a bag as well. You are right about Renexa. that is something the company has never kept us informed on. They filed that under the new regs so the FDA was to give a response within 10 months. So only way they can get approval is assuming they did not receive any CRL.

Honestly they had the chance to get on the leading edge f so many drugs and they blow it every time. Regabatin for one. They have been siting on that since 2015 knowing they needed a partner. Had they partnered back then they would have been set to roll it out before the end of the Lyrica patent. Now they will have to compete with generics. Seroquel! they fail to capitalize on that and companies who got approval AFTER IPCI got more market share than we did. to this day they have not made a effort to sell it nor have they held MNK accountable.

It is become apparent, Odidi thinks he is successful merely because he obtains a patent or an approval rather than the actual success of the company. which is why he feels he is justified in his millions of salary and bonuses a year while not doing anything to provide shareholder value but only diluting it.

approved drugs sitting on a shelf collecting dust. approved drugs which are partnered not being marketed properly and doing nothing. proposed NDA's sitting on a shelf since 2015 not being partnered so no progress on the pipeline. Yet, he feels that is success worthy of top notch pay and bonuses. Worse of all we have a BOD that does nothing about it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y